Latest Quarterly Report
Filed: 2026-05-06
Key Insights
- The filing contains extensive structured data references for multiple revenue segments including ORLADEYO (primary product), Peramivir, and license/collaborative R&D arrangements, indicating diversified revenue streams but requiring detailed review of actual financial metrics.
- Multiple references to the Astria acquisition (dated 2026-01-23) suggest a significant corporate transaction completed in Q1 2026, which will materially impact operating expenses, R&D costs, and SG&A expenses for the quarter.
- The filing shows geographic concentration risk data for US sales and detailed fair value measurements across multiple investment security types (money market funds, government agencies, corporate debt), indicating active treasury management and potential liquidity considerations.
- References to royalty arrangements with RPI 2019 Intermediate Finance Trust tied to ORLADEYO sales at multiple tiers (under $350K, $350K-$550K, over $550K annually) demonstrate structured revenue-sharing obligations that will impact net margins as sales scale.